StemCell Therapy

11-11-2011 07:19 Stem Cell Therapy cream is believed to remove wrinkles and fine lines.

See the article here:
BioLogic Stem Cell Therapy Cream - Video

18-11-2011 14:29 Dr Tony Talebi discusses stem cell transplantation in Myeloma with Dr Ratzan. For further discussion visit http://www.HemOnc101.com

Continue reading here:
Dr Tony Talebi discusses stem cell transplantation in Myeloma with Dr Ratzan - Video

08-06-2011 19:18 (Part 7 of 8) Dan Desmond, spoke at the "Spotlight on Disease Team Awards: ALS," an educational event presented at the CIRM Governing Board meeting on June 23, 2010. Desmond has a Master of Arts in counseling psychology and is founding director of Family Focus Christian Counseling, Inc. The CIRM-hosted event was presented in San Diego, California.

Originally posted here:
Lou Gehrig's Disease (ALS): Stem Cell Therapy - A Patient's Perspective - Video

27-12-2011 23:01 The Brownsville man is now behind bars and facing multiple federal charges. Prosecutors allege Morales was part of a cross-border scheme.

Read the rest here:
Brownsville man arrested for stem cell scheme - Video

18-11-2011 14:29 Dr Tony Talebi discusses stem cell transplantation in Myeloma with Dr Ratzan.

Go here to see the original:
Dr Tony Talebi discusses stem cell transplantation in Myeloma with Dr Ratzan - Video

18-11-2011 14:34 Dr Tony Talebi discusses treatment of multiple myeloma in non stem cell transplantation candidate patients with Dr Ratzan. For further discussion visit http://www.HemOnc101.com Treatment of multiple myeloma Multiple myeloma is characterized by the neoplastic proliferation of a single clone of plasma cells producing a monoclonal immunoglobulin antibody. This clone of plasma cells proliferates in the bone marrow and often results in extensive skeletal destruction with osteolytic lesions, and/or pathologic fractures.

Continue reading here:
Dr Tony Talebi discusses treatment of multiple myeloma patients with Dr Ratzan - Video

28-10-2011 17:23 Dr Tristan McKay of the William Harvey Research Institute at Queen Mary University of London presents the current status of stem cell therapies for human disease. He highlights the opportunities and controversies in the field, and sets out the challenges ahead

See original here:
BSGT-ESGCT What is Stem Cell Therapy? - Video

17-11-2011 05:23 Dr Nandini talking about Stem Cell Therapy for Brain and Spine Disorders on DD Sahyadri. Stem cell therapy done at neurogen brain and spine institute pvt ltd. http://www.neurogen.in Tell: +91 9920 200 400 , 022 25281610 , 022 25283706

Read more:
Stem Cell Therapy for Brain and Spine Disorders, Mumbai - Video

16-12-2011 14:38 Learn about adult stem cells and how they can help you in the areas of orthopedic and degenerative disease, sports injuries, pain in the knees, shoulders, elbows, and back or spinal injuries. Dr. Damon Noto talks about stem cell treatment on Channel 12 Health program

Read the rest here:
Stem Cell Therapy News Channel 12 Health - Dr Damon Noto.flv - Video

(HealthDay News) -- Many older Americans get screened for colon, breast, prostate and cervical cancer even though guidelines recommend against routinely screening the elderly, a new study finds.

As the population of the United States continues to age, balancing good health care with costs will be a continuing battle, experts say. "In an era of escalating health care utilization and expenditures in the United States, identifying areas for cost containment while concurrently improving quality of care in our health care system is increasingly paramount," said lead researcher Keith Bellizzi, an assistant professor of human development and family studies at the University of Connecticut in Storrs.

"Perhaps this area of health care warrants further attention," Bellizzi added.

Currently, nearly 37 million people in the United States are 65 and older, and that number will probably double by 2030. Historically, older adults have been excluded from cancer clinical trials, so what is known about the effectiveness of screening in seniors is limited, he said.

The U.S. Preventive Services Task Force recommends against routine screening for breast, colorectal, and prostate cancer at age 75 and beyond, and advises against cervical cancer testing after 65, according to the study. Read more...

Ayurtox for Body Detoxification

Source:
http://feeds.feedburner.com/integratedmedicine

Tweet 

What follows is the record of "classifications" done by the ATMP CAT in 2011 related to anything I would call "cell therapies". 


In my opinion there are a couple surprises. I'm surprised at the non-cardiac cells (MNCs, CD133s, and MSCs) for cardiac disease/repair being designated TEPs. I'm also surprised at the islets not being classified as an ATMP.


I've tapped into my European and/or regulatory colleagues to help explain those two as well as help us draw any other conclusions or observations we can make in terms of how the CAT is thinking based on the compendium of classifications we have to-date.  I'll post an update here when I have something useful.
______


In January, the following product was classified as a tissue engineered product - not combined:

• Layer of autologous corneal epithelium containing stem cells intended for the treatment of extended corneal lesions

In April, the following product was classified as a tissue engineered product, combined: 

• Allogeneic human fibroblasts cultured onto a biodegradable matrix, intended for use of conditions in the therapeutic area of dermatology

In May, the following product was classified as a somatic cell therapy medicinal product: 

• Heterologous human adult liver-derived progenitor cells, intended for the treatment of inborn errors of liver metabolis

In July, the following product was classified as a Tissue Engineered Product, non-combined:

• Suspension of allogeneic bone-marrow derived osteoblastic cells, intended for the treatment of non-union, delayed union or other fractures. 

In September, the following product was classified as a Tissue Engineered Product, non-combined:

• Autologous mesenchymal stem cells (MSC), intended for the treatment of chronic heart failure symptoms by improvement in exercise capacity of NYHA class II and III chronic heart failure patients receiving standard therapy

     and the following product was not classified as an ATMP: 

• Human islets of Langerhans, intended for: Post pancreatectomy for benign pancreatic pathologies (autologous); Treatment of severe forms of type 1 diabetes (Allogeneic)

In October, the following product was classified as a somatic cell therapy medicinal product: 

• Autologous dendritic cell (DCs) immunotherapy consisting of autologous mature DCs coelectroporated with autologous RCC IVT RNA and synthetic CD40L IVT RNA, intended for the treatment of patients with advanced renal cell carcinoma

In November, the following products were classified as tissue-engineered products:

• Concentrate of autologous bone marrow mononuclear cells (MNC), intended for improvement of heart function and quality of life in patients with chronic ischaemic heart disease and after MI.
• CD 133+ Autologous bone marrow derived stem cells, intended for Improvement of heart function (LVEF) and quality of life in patients with chronic ischemic heart disease and after MI

In December, the following product was classified as somatic cell therapy medicinal product:

• Autologous CD4+ T cells targeted to cells presenting class II restricted epitopes, intended forthe treatment of autoimmune diseases with MHC restricted specific immunity e.g. multiple sclerosis, type I diabetes or graft rejection.

http://www.celltherapyblog.com hosted by http://www.celltherapygroup.com

Source:
http://feeds.feedburner.com/CellTherapyBlog

Inevitably, year-end lists invite plenty of debate and criticism, and Scientific American 's is no exception. Certainly, we could have included the discovery of new worlds beyond our solar system, including Kepler 22 b, an exoplanet in the "Goldilocks" zone of habitability, as well as the first known Earth-size exoplanets . Or noted the accumulating evidence suggesting that hydraulic fracturing, or fracking, to retrieve natural gas is likely to contaminate water supplies. (Final New York State regulations, expected in mid-2012, could determine the future of fracking in the U.S.)

[More]

Source:
http://rss.sciam.com/sciam/topic/gene-therapy

(HealthDay News) -- Many older Americans get screened for colon, breast, prostate and cervical cancer even though guidelines recommend against routinely screening the elderly, a new study finds.

As the population of the United States continues to age, balancing good health care with costs will be a continuing battle, experts say. "In an era of escalating health care utilization and expenditures in the United States, identifying areas for cost containment while concurrently improving quality of care in our health care system is increasingly paramount," said lead researcher Keith Bellizzi, an assistant professor of human development and family studies at the University of Connecticut in Storrs.

"Perhaps this area of health care warrants further attention," Bellizzi added.

Currently, nearly 37 million people in the United States are 65 and older, and that number will probably double by 2030. Historically, older adults have been excluded from cancer clinical trials, so what is known about the effectiveness of screening in seniors is limited, he said.

The U.S. Preventive Services Task Force recommends against routine screening for breast, colorectal, and prostate cancer at age 75 and beyond, and advises against cervical cancer testing after 65, according to the study. Read more...

Ayurtox for Body Detoxification

Source:
http://feeds.feedburner.com/integratedmedicine

Tweet 

What follows is the record of "classifications" done by the ATMP CAT in 2011 related to anything I would call "cell therapies". 


In my opinion there are a couple surprises. I'm surprised at the non-cardiac cells (MNCs, CD133s, and MSCs) for cardiac disease/repair being designated TEPs. I'm also surprised at the islets not being classified as an ATMP.


I've tapped into my European and/or regulatory colleagues to help explain those two as well as help us draw any other conclusions or observations we can make in terms of how the CAT is thinking based on the compendium of classifications we have to-date.  I'll post an update here when I have something useful.
______


In January, the following product was classified as a tissue engineered product - not combined:

• Layer of autologous corneal epithelium containing stem cells intended for the treatment of extended corneal lesions

In April, the following product was classified as a tissue engineered product, combined: 

• Allogeneic human fibroblasts cultured onto a biodegradable matrix, intended for use of conditions in the therapeutic area of dermatology

In May, the following product was classified as a somatic cell therapy medicinal product: 

• Heterologous human adult liver-derived progenitor cells, intended for the treatment of inborn errors of liver metabolis

In July, the following product was classified as a Tissue Engineered Product, non-combined:

• Suspension of allogeneic bone-marrow derived osteoblastic cells, intended for the treatment of non-union, delayed union or other fractures. 

In September, the following product was classified as a Tissue Engineered Product, non-combined:

• Autologous mesenchymal stem cells (MSC), intended for the treatment of chronic heart failure symptoms by improvement in exercise capacity of NYHA class II and III chronic heart failure patients receiving standard therapy

     and the following product was not classified as an ATMP: 

• Human islets of Langerhans, intended for: Post pancreatectomy for benign pancreatic pathologies (autologous); Treatment of severe forms of type 1 diabetes (Allogeneic)

In October, the following product was classified as a somatic cell therapy medicinal product: 

• Autologous dendritic cell (DCs) immunotherapy consisting of autologous mature DCs coelectroporated with autologous RCC IVT RNA and synthetic CD40L IVT RNA, intended for the treatment of patients with advanced renal cell carcinoma

In November, the following products were classified as tissue-engineered products:

• Concentrate of autologous bone marrow mononuclear cells (MNC), intended for improvement of heart function and quality of life in patients with chronic ischaemic heart disease and after MI.
• CD 133+ Autologous bone marrow derived stem cells, intended for Improvement of heart function (LVEF) and quality of life in patients with chronic ischemic heart disease and after MI

In December, the following product was classified as somatic cell therapy medicinal product:

• Autologous CD4+ T cells targeted to cells presenting class II restricted epitopes, intended forthe treatment of autoimmune diseases with MHC restricted specific immunity e.g. multiple sclerosis, type I diabetes or graft rejection.

http://www.celltherapyblog.com hosted by http://www.celltherapygroup.com

Source:
http://feeds.feedburner.com/CellTherapyBlog

Inevitably, year-end lists invite plenty of debate and criticism, and Scientific American 's is no exception. Certainly, we could have included the discovery of new worlds beyond our solar system, including Kepler 22 b, an exoplanet in the "Goldilocks" zone of habitability, as well as the first known Earth-size exoplanets . Or noted the accumulating evidence suggesting that hydraulic fracturing, or fracking, to retrieve natural gas is likely to contaminate water supplies. (Final New York State regulations, expected in mid-2012, could determine the future of fracking in the U.S.)

[More]

Source:
http://rss.sciam.com/sciam/topic/gene-therapy

04-05-2011 09:15 StemFlo® is a cutting-edge blend of antioxidants and enzymes that support optimal blood circulation. gmp.stemtechbiz.com Designed to support the "flow" of adult stem cells and nutrients to all parts of the body, StemFlo assists and supports your body's adult stem cell nutrition needs.

Read more:
StemFlo - Blood Circulation Enhancer, Antioxidant and More!.flv - Video

Many of our patients travel to Guangzhou from all over the world for medical treatment and tourism. China medical tourism can help with becoming a patient, travel arrangements and language assistance. If you want to know more about our services, please browse the web:htttp://www.medicaltourism.hk/ or mail to us: giels-x@medicaltourism.hk firstcare-china@hotmail.com Diagnosis Angelica suffered brain damage due to lack of oxygen and was diagnosed with PVL or Cystic Periventricular Leukomalacia.

Read more:
China medical tourism--Cerebral Palsy--stem cells therapy - Video

Many of our patients travel to Guangzhou from all over the world for medical treatment and tourism. China medical tourism can help with becoming a patient, travel arrangements and language assistance. If you want to know more about our services, please browse the web:htttp://www.medicaltourism.hk/ or mail to us: giels-x@medicaltourism.hk firstcare-china@hotmail.com PATIENTEXPERIENCE - BRAININJURY NAME: Jessica McAfee AGE: 22 COUNTRY: USA DIAGNOSIS: Three years ago, the patient was involved in a car accident which left her brain damaged.

View post:
China medical tourism--Brain Injury--stem cells therapy - Video

GeneCell International is one of the leaders in the field of stem cell banking. We operate a laboratory that focuses on processing and cryopreserving of stem cells derived from umbilical cord blood, dental pulp, adipose tissue, other tissues, and cells that can be cryogenically preserved. Our purpose is to provide families with the highest quality stem cell products and services and the best customer service, unparalleled scientific excellence and innovative leadership in the areas of stem cell collection, processing and cryopreservation

See the article here:
GeneCell International on Miami Moms - Video

Stem cells harvested from your fat can be cryopreserved for potential future medical use. The intial harvesting is performed in office, by Dr. Walter Tom under local anesthesia

Follow this link:
Could Fat Save Your Life - Video